1
Participants
Start Date
December 1, 2020
Primary Completion Date
May 7, 2024
Study Completion Date
May 7, 2024
Sulfur hexafluoride lipid-type A microspheres
Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
The Children's Hospital of Philadelphia, Philadelphia
Collaborators (1)
Bracco Diagnostics, Inc
INDUSTRY
Children's Hospital of Philadelphia
OTHER